Evidence map›Paper›PMID 31489032›Full record

ArticleTherapeutic advances in neurological disorders2019

Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases.

Jeremias Motte, Janina Kneiphof, Katrin Straßburger-Krogias, Kalliopi Pitarokoili, Anna Lena Fisse, Ludwig Kappos, Ralf Gold

Open access · goldAbstract readCase Reports
In one paragraph

Article in Therapeutic advances in neurological disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Multiple sclerosis and intracellular cobalamin defect (Molecular genetics and metabolism reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jeremias MotteDepartment of Neurology, Ruhr-University Bochum, St Josef- Hospital, Gudrunstrasse 56, Bochum 44791, Germany.ORCID https://orcid.org/0000-0002-6624-8565
Janina KneiphofDepartment of Neurology, Ruhr-University Bochum, Bochum, Germany.
Katrin Straßburger-KrogiasDepartment of Neurology, Ruhr-University Bochum, Bochum, Germany.
Kalliopi PitarokoiliDepartment of Neurology, Ruhr-University Bochum, Bochum, Germany.
Anna Lena FisseDepartment of Neurology, Ruhr-University Bochum, Bochum, Germany.ORCID https://orcid.org/0000-0003-0493-8656
Ludwig KapposNeurologic Clinic and Policlinic, University Hospital Basel, Basel, Switzerland.
Ralf GoldDepartment of Neurology, Ruhr-University Bochum, Bochum, Germany.
Ruhr University Bochum · DESt. Josef-Hospital · DEUniversity Hospital of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cblC defect is the most common inborn error of cobalamin (Cbl) metabolism. Clinical severity and presentation of the cblC defect ranges from death to mild disability. Only 71 cases of late-onset cblC defect have been described in the literature. We provide the 41-year follow up of two siblings with a late-onset cblC defect, first described after initial diagnosis in 1996. While one of the siblings showed initial symptoms resembling multiple sclerosis with a good response to corticosteroids, the other sister showed only subclinical signs of the disease. The course of the first case was characterized by a severe deterioration and intensive-care therapy after respiratory failure. After diagnoses and Cbl treatment, the patient survived and showed a pronounced improvement of the symptoms. Both sisters have an active life and gave birth to healthy children. The reason for the initial improvement after corticosteroids could not be explained by the classical metabolic pathways of Cbl. Recent studies have suggested that Cbl plays an important role as a regulator of the balance between neurotrophic and neurotoxic factors in the central and peripheral nervous system (CNS and PNS). This first long-term follow up revealed that ultra-high-dose intramuscular Hydroxocobalamin (OH-Cbl) treatment can effectively protect patients from disease progression. It underlines the importance of diagnostic vigilance and laboratory work up even in cases without typical hematologic signs of Cbl deficiency. Cbl-related diseases are often a chameleon and must always be considered in the differential of demyelinating diseases of the PNS and CNS. The case supports the theory that it is not only the classical biochemical pathways that play a key role in Cbl deficiency, especially with regard to neurological symptoms.

Indexed as

cblC defectcobalaminmultiple sclerosismyelopathythrombosisvitamin B12 metabolism

Identifiers

PMID31489032
PMCPMC6710698
OpenAlexW2969915661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.